Synbio Tech Inc. (1295) Fair Value & Analysis
Healthcare · TW · Market cap 1.7B TWD (≈ $52.6M) · ISIN TW0001295004
What is Synbio Tech Inc. really worth?
Below-average quality, trading 31% below our fair value of 66.16 TWD.
As of Aug 17, 2026, the fair value of Synbio Tech Inc. is 66.16 TWD per share against a price of 45.35 TWD, so the fair value sits 46% above the price. A model estimate blended from multiple valuation models, recalculated regularly.
Strengths
Risks
For context
Fair value as of: Aug 17, 2026
From 8 valuation models · updated 20 days ago
Share price −2.3% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The large discount to fair value meets weak quality (32/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case (49.62 TWD). The market is more pessimistic than our downside scenario.
Price vs Fair Value (3 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 17, 2026.
How to read this chart
33‑month range 45.30 TWD – 149.22 TWD · fair‑value band 49.62 TWD – 82.70 TWD · the 45.35 TWD price screens below the 66.16 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 17, 2026.
Analysis
Synbio Tech Inc. (1295) currently trades at 45.35 TWD, while our model-based Fair Value estimate is 66.16 TWD, implying the stock looks roughly 31.5% undervalued today. The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector. Bull case: the Multiples group reads highest at a median of 53.86 TWD per share, and 4 of the 8 models we run sit above the 45.35 TWD price. Bear case: the Asset-Based group reads lowest at 25.77 TWD, and 4 of the 8 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Synbio Tech Inc. generated revenue of 1.0B TWD at a net margin of 14.7%. Revenue declined 8.2% year over year. It earns a return on equity of 13.2%. Net debt stands at 981M TWD. Fundamentals as of Aug 17, 2026
Our scenario range runs from 49.62 TWD (bear case) to 82.70 TWD (bull case); at 45.35 TWD, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 70% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −56% fair-value upside, at 46%, 1295 screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly 1.56 TWD per share, which is 2.4 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 8 models by family
Widest divergence: Multiples (53.86 TWD) versus Asset-Based (25.77 TWD). Highest evidence: Residual Income (75).
Notify me when 1295 reaches fair value
Put 1295 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 17, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 36 · Market factors (momentum, volatility) 29
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Synbio Tech Inc. manufactures and sells human healthcare products and probiotics for animals. It offers lactobacillus plantarum powder and derivatives of fermented lactic acid bacteria, as well as probiotics for dietary supplements, pets, economic animals, and plant preservation.
Full company description
Synbio Tech Inc. manufactures and sells human healthcare products and probiotics for animals. It offers lactobacillus plantarum powder and derivatives of fermented lactic acid bacteria, as well as probiotics for dietary supplements, pets, economic animals, and plant preservation. The company also provides single probiotic strain and multi strain probiotics, and functional strain. Its functional strain includes SynForU-MemoryUp, a solution for brain health; Lactobacillus plantarum TWK10 for exercise performance; ABKEFIR to improve digestive and promote human health; SynForU-ImmuUp for immune system; SynForU-GastroKeep, a stomach care probiotic; SynForU-HepaAid, a liver care probiotic; SynForU-HerCare, which inhibits the growth of fungal and bacterial pathogens, as well as maintains the vaginal microbiome in proper balance; multi strain probiotics; and postbiotics, which include LDL557, for modulate the immune system, reduce inflammation and joint pain, and M1, to support immune system. In addition, it offers GABAbiotics-Adaptogenic Postbiotics, Synbio-Oligo, and Yogurt Powder for food applications; pet health solutions, including SYNPET functional probiotics, SYNPET GO for muscle and joint care, SYNPET IMMU for skin and immunity care, SYNPET FIT for weight management, and SYNPET TRENAL for kidney health care and functional prebiotics. Further, the company provides SYNFERM Pigment, a lactobacillus strains that rapidly produce lactic acid; SYNFERM Feed for digestion and rapid nutrient uptake in poultry and livestock; and SYNFERM Corn Silage for ruminant animals with high digestible nutrients. Additionally, it offers SYNSEA FeedAd, a probiotic complex for aquatic livestock; and SYNSEA Clean EX for reduction in the concentrations of nitrites and ammonia in water, as well as antibiotic-free probiotic solutions for poultry, swine, aquaculture, ruminant, and pigmented plants. The company was incorporated in 2000 and is based in Kaohsiung, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Synbio Tech Inc. reported revenue of 1.0B TWD in FY2025 versus 856M TWD in FY2021, a compound +5.0%/yr. Reported net income was 176M TWD in FY2025, compounding +2.4%/yr from FY2021.
Watch 1295: get an alert when its fair value changes →
Peer Group
Biotechnology · 627 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $547.55 | $278.78 | −49% |
| Regeneron Pharmaceuticals, Inc REGN | $807.71 | $594.40 | −26% |
| argenx SE ARGX | €877.60 | €292.84 | −67% |
| BeOne Medicines AG 688235 | ¥271.00 | ¥47.36 | −83% |
| Samsung Biologics Co 207940 | 1,518,000 KRW | 1,055,793 KRW | −30% |
| Alnylam Pharmaceuticals, Inc ALNY | $228.61 | $51.70 | −77% |
| Royalty Pharma plc RPRX | $60.58 | $24.22 | −60% |
| Celltrion, Inc 068270 | 190,700 KRW | 74,519 KRW | −61% |
| BioNTech SE BNTX | $103.76 | $45.70 | −56% |
| Incyte Corporation INCY | $123.22 | $115.79 | −6% |
Compare Synbio Tech Inc. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Synbio Tech Inc. (1295) overvalued or undervalued?
What is the fair value of 1295?
What is the quality score of 1295?
What is the price target for Synbio Tech Inc. (1295)?
What is the Synbio Tech Inc. stock forecast for 2026?
What is the revenue of Synbio Tech Inc. (1295)?
What is the net profit margin of 1295?
Does Synbio Tech Inc. pay a dividend?
Watch Synbio Tech Inc. in the live analysis
One click puts Synbio Tech Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.